Efficacy and safety of modified tetracycline dosing in a quadruple therapy for Helicobacter pylori: A retrospective single center study

Table 1 Demographic and clinical data of patients according to eradication outcome

Outcome	Successful	Failed	P
N	365	29
Age (mean ± SD)	45.90 ± 13.95	52.5 ± 12.2	0.319
Age range	(20-77)	(27-68)
Age (≤ 50)	221	15	0.046
Gender (M/F)	122/243	44/74	0.685
Smoking (Yes/No)	31/334	5/29	0.168
Drinking (Yes/No)	61/304	8/29	0.138
Education			0.099
Primary school	61	19
Middle school	138	40
College	158	57
GC family history			0.361
Yes/No	15/350	2/27
Endoscopy diagnosis			0.597
Gastritis	247	22
Ulcer	45	2
Unknown	73	5
Intestinal metaplasia			0.557
No	176	17
Yes	113	7
Unknown	76	5
Treatment			0.959
500 mg b.i.d.	145	12
750 mg b.i.d.	110	8
500 mg t.i.d.	110	9
Treatment line1			0.026
First line	291	18
Rescue therapy	74	11
PPI			0.762
Pantoprazole	151	14
Esomeprazole	69	4
Rabeprazole	139	11
Lansoprazole	6	0
Bismuth			0.351
Bismuth potassium citrate	302	22
Colloidal bismuth pectin	63	7
Type 2 diabetes	18	6	0.020
Hypertension	48	15	< 0.0001
Hyperlipidemia	19	7	< 0.0001
Penicillin allergy	70	6	0.843

¹Recording this treatment as start of frequency. Rescue therapy was defined as patients who had eradicated therapy once or more but failed.

P values were from two-side comparisons the differences between two groups. M: male; F: female; 500 mg b.i.d.: Tetracycline twice daily; 750 mg b.i.d.: Tetracycline twice daily; 500 mg t.i.d.: Tetracycline three times daily.